Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and share sales in Adaptive Biotechnologies Corp. Between April 14 and April 16, 2026, she exercised stock options to acquire a total of 44,166 shares of common stock at an exercise price of $8.46 per share.
Over the same period, she sold 57,180 shares of common stock in open-market transactions, including sales reported at weighted average prices of $14.18, $14.61 and $14.56 per share. These transactions were carried out under a Rule 10b5-1 trading plan adopted on November 18, 2025. Following the transactions, she directly holds 408,160 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and related stock sales. She exercised options to acquire 44,166 shares of common stock at exercise prices of $7.27 and $8.46 per share, then sold 57,180 shares in open-market transactions at weighted average prices generally in the mid‑teens per share. These trades, executed on April 9, 10, and 13, were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. After the transactions, Rubinstein directly owned 421,174 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised stock options and sold shares in a planned transaction. On April 8, 2026, Lo exercised options to acquire 2,344 shares of common stock at $3.99 per share, then sold 22,564 shares of common stock in an open-market sale at a weighted average price of $15.07 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on September 15, 2025. After the transactions, Lo owns 271,154 shares directly and an additional 2,500 shares indirectly through a spouse.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported an open-market sale of 10,000 shares of common stock on April 8, 2026 at a weighted-average price of $14.85 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025. Following this transaction, Robins directly holds 1,512,058 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported open-market sales of company common stock executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025.
He sold 83,332 shares on April 6, 2026 at a weighted average price of $14.41 per share in multiple trades between $14.19 and $14.84. He then sold 37,263 shares on April 8, 2026 at a weighted average price of $15.19 per share, with individual trades between $15.00 and $15.53.
Across both transactions, Robins sold 120,595 shares and directly held 2,180,518 shares of Adaptive Biotechnologies common stock following the most recent sale.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported option exercises and share sales in a planned series of trades. She exercised stock options for 56,047 shares of common stock at exercise prices of $7.27 and $12.14 per share and sold 69,061 shares in open‑market transactions at weighted average prices ranging from about $13.39 to $15.48 between April 6 and April 8, 2026. After these transactions, she directly held 434,188 shares of common stock and retained vested stock options representing 37,553 shares. The filing notes that all transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 18, 2025.
ADPT affiliate reported proposed resale of Common Stock under Form 144. The cover lists 10,000 shares associated with a broker, an aggregate figure of $148,400, and 153,981,561 shares outstanding as of 04/08/2026. The filing also lists multiple recent dispositions by Harlan Robins, including sales on 02/02/2026, 02/03/2026, 03/02/2026, and 03/03/2026 totaling several reported share amounts and proceeds.
Chad M. Robins reported proposed and recent transactions in Common Stock under a Form 144. The filing lists multiple individual sales and proposed sales of common stock, including transactions in February–April 2026. Examples in the filing include a sale of 99,225 shares for $1,589,941.71 on 02/27/2026 and a sale of 96,323 shares for $1,546,542.82 on 03/02/2026. The document is a notice of proposed sale by an affiliate and lists several executed dispositions in the prior three months.
ADPT affiliate files Form 144 to sell shares. The filing lists 2,344 shares to be sold upon exercise of stock options dated 04/08/2026 and 20,220 shares issuable under Restricted Stock Units dated 03/04/2025. The filing also reports recent 10b5-1 sales: 30,593 shares on 03/11/2026 for $430,622.58, 38,074 shares on 03/05/2026 for $574,536.66, and 79,590 shares on 01/12/2026 for $1,411,393.35.
Adaptive Biotechnologies (ADPT) notice of proposed sales of Common Stock by an affiliate under Form 144. The excerpt lists multiple proposed sale transactions by Chad M. Robins with individual trades ranging from 4,452 to 99,225 shares and corresponding gross proceeds shown per trade.